Antibodies which block PD-1/PD-L1 interactions have demonstrated that in select subtypes of HL and NHL, the PD-1 ligands are over-expressed due to a genetic amplification of the loci encoding them [132–134]. The gene discussed is PDCD1; the disease is non-Hodgkin lymphoma.